Immune checkpoint: The novel target for antitumor therapy

Xianghu Jiang; Guohong Liu; Yirong Li; Yunbao Pan

doi:10.1016/j.gendis.2019.12.004

您当前的位置：

首页 >

文章列表页 >

Immune checkpoint: The novel target for antitumor therapy

Review article | 更新时间：2022-06-24

- Immune checkpoint: The novel target for antitumor therapy
- Immune checkpoint: The novel target for antitumor therapy
- Genes & Diseases 2021年8卷第1期
- 作者机构：
  
  1. Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan University,Hubei,Wuhan,PR China,430072
  2. Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan University,Hubei,Wuhan,PR China,430072
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2019.12.004
  中图分类号：
- 纸质出版日期：2021，
  
  网络出版日期：2021-1-1，
扫描看全文
Xianghu Jiang, Guohong Liu, Yirong Li, 等. Immune checkpoint: The novel target for antitumor therapy[J]. Genes & Diseases, 2021,8(1).

Xianghu Jiang, Guohong Liu, Yirong Li, et al. Immune checkpoint: The novel target for antitumor therapy[J]. Genes & Diseases, 2021,8(1).
Xianghu Jiang, Guohong Liu, Yirong Li, 等. Immune checkpoint: The novel target for antitumor therapy[J]. Genes & Diseases, 2021,8(1). DOI： 10.1016/j.gendis.2019.12.004.

Xianghu Jiang, Guohong Liu, Yirong Li, et al. Immune checkpoint: The novel target for antitumor therapy[J]. Genes & Diseases, 2021,8(1). DOI： 10.1016/j.gendis.2019.12.004.

摘要

Abstract

Inhibitory checkpoint molecules include programmed cell death-1 (PD-1)

programmed cell death ligand-1 (PD-L1)

cytotoxic T lymphocyte antigen-4 (CTLA-4)

human endogenous retrovirus-H Long terminal repeat-associating 2 (HHLA2)

B7 homolog 4 protein (B7-H4)

T cell membrane protein-3 (TIM-3) and Lymphocyte-activation gene 3 (LAG-3)

which are up-regulated during tumorigenesis. These pathways are essential to down-regulate the immune system by blocking the activation of T cells. In recent years

immune checkpoint blockers (ICBs) against PD-1

PD-L1

CTLA-4 or TIM-3 has made remarkable progress in the clinical application

revolutionizing the treatment of malignant tumors and improving patients' overall survival. However

the efficacy of ICBs in some patients does not seem to be good enough

and more immune-related adverse events (irAEs) will inevitably occur. Therefore

biomarkers research provides practical guidance for clinicians to identify patients who are most likely to benefit from or exhibit resistance to particular types of immune checkpoint therapy. There are two points in general. On the one hand

given the spatial and temporal differential expression of immune checkpoint molecules during immunosuppression process

it is essential to understand their mechanisms to design the most effective individualized therapy. On the other hand

due to the lack of potent immune checkpoints

it is necessary to combine them with novel biomarkers (such as exosomes and ctDNA) and other anticancer modalities (such as chemotherapy and radiotherapy).

关键词

Keywords

Circulating tumor DNA (ctDNA)Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)ExosomeImmune checkpointLymphocyte-activation gene 3 (LAG-3)Programmed cell death protein ligand 1 (PD-L1)Programmed death-1 receptor (PD-1)T cell immunoglobulin domain and mucin domain 3 (TIM-3)

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Integrative transcriptome analysis identifies MYBL2 as a poor prognosis marker for osteosarcoma and a pan-cancer marker of immune infiltration

JAG1 enhances angiogenesis in triple-negative breast cancer through promoting the secretion of exosomal lncRNA MALAT1

Does burning fat make tumor immune hot? Discovery of CD47 overexpression by radiation induced fatty acid oxidation

The combination of novel immune checkpoints HHLA2 and ICOSLG: A new system to predict survival and immune features in esophageal squamous cell carcinoma

Circulating exosome-like vesicles of humans with nondiabetic obesity impaired islet β-cell proliferation, which was associated with decreased Omentin-1 protein cargo